FDAIterum Ist.

antibiotics are a revolutionary breakthrough in theof theMedical(http://Health(http:// which makes it possible to treat once-fatal infectionsHowever, with the spread of antibiotic use, microorganisms are resistant to antibioticstoday, Itrum(http://announced that the U.SFDA(http://grantite its(http://(QIDP) for the development of innovative antibioticsulopenem qualified infectious diseasesproducts for the treatment of four indications, including community-acquired bacterial pneumonia, acute bacterial prostatitis, gonorrhea urethritis, and pelvic inflammatory diseaseas many as seven types of adaptations that qualify for QIDP with new antibioticsIn 2017, it has been qualified for QIDP treatment for non-complex urinary tract infections (uUTI), complex urinary tract infections (cUTI), and complex abdominal infections (cIAI)at the same time the FDA granted sulopenem fast-track eligibility for these 7-way indicationsAn important way to solve the problem of antibiotic resistance is to develop new antibioticsThe sulopenem developed by Iterum is a broad-spectrum carbon ilostene antibiotic that can be injected orallyin in vitrotrial series(http://, sulopenem is active against Gram-negative, Gram-positive and anaerobic bacteria that have become resistant to other antibioticscurrently, sulopenem is used in clinical Phase 3 trials to treat uUTI, cUTI, and cIAI